---
title: "What will the FDA's decision be on Venglustat by Sanofi in 2026?"
canonical_url: https://betcrypto.now/events/what-will-the-fdas-decision-be-on-venglustat-by-sanofi-in-2026
status: live
trading_closes_at: 2027-01-01T04:59:00+00:00
total_volume_usd: 968.6
venues: ["Kalshi"]
categories: ["Markets"]
prices_as_of: 2026-10-09T12:31:07+00:00
publisher: BetCrypto
data_api: https://betcrypto.now/api/v1/events/what-will-the-fdas-decision-be-on-venglustat-by-sanofi-in-2026
---

# What will the FDA's decision be on Venglustat by Sanofi in 2026?

Live · $969 traded · listed on Kalshi

## About

If the FDA's decision on Venglustat by Sanofi in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. 

Venglustat is an oral small-molecule drug developed by Sanofi that works by slowing down the body's production of a fatty substance called glucosylceramide, which builds up to harmful levels in people with Gaucher disease — think of it like adjusting a factory's output dial rather than cleaning up the mess after the fact. It belongs to a class called substrate reduction therapy (SRT), meaning it targets the upstream source of the problem rather than replacing a missing enzyme. Because it is a small molecule taken by mouth and designed to cross into the brain, it has potential to address the neurological symptoms that older enzyme-based treatments cannot reach.

_From Kalshi's listing._

## Main market

| Outcome | Probability | Cheapest | Kalshi |
|---|---|---|---|
| Yes | 83% | 87¢ on Kalshi | 87¢ |
| No | 17% | 21¢ on Kalshi | 21¢ |

## Open on a venue

- [Kalshi](https://betcrypto.now/go/e/2109?via=md)

---

Probability is the cross-venue consensus (book midpoints, 0–100%). Venue columns are what buying costs there (the ask). Prices move constantly; re-check at the canonical URL or https://betcrypto.now/api/v1/events/what-will-the-fdas-decision-be-on-venglustat-by-sanofi-in-2026.

BetCrypto is an odds-comparison and information service. It accepts no wagers and gives no betting or financial advice; prediction-market availability depends on where you live.